Abstract 389P
Background
Patients with head and neck cancers often require multimodality treatments. Therefore, cross-resistance to various treatments that are employed for these patients poses a significant therapeutic problem. A better understanding of therapeutic cross-resistance could lead to methods which will circumvent cross-resistance. Herein, we explore erlotinib (anti-EGFr, TKI) and radiation sensitivity in human head and neck cancer cells with acquired resistance to cetuximab (anti-EGFr mAb).
Methods
Two human head and neck squamous cell cancers were utilized for these for these studies; UM-SCC-1 and UM-SCC-6. It has been previously reported that UM-SCC-1 is substantially more radioresistant than UM-SCC-6 (IJROBP 29 (2):243-247,1994). We have previously reported on cell lines that were created by continuous exposure of the above cell lines to 5 μg/ml cetuximab (Biochem Biophys Res Common 517(1): 36-42, 2019 and PLoS ONE 15(2) eo229077,1-14, 2020). Therefore, two cetuximab-resistant cell lines were created; UM-SCC-1R and UM-SCC-6R. Radiation sensitivity and erlotinib sensitivity were investigated through the use of standard proliferation assays and apoptosis assays as previously described (BMC Cancer 15:673, 2015).
Results
For the assessments of radiation sensitivity and erlotinib sensitivity, comparisons were made between the two cetuximab-resistant cell lines (UM-SCC-1R and UM-SCC-6R) with their respective parental cell lines (UM-SCC-1 and UM-SCC-6). It was discovered that the two cetuximab resistant cell lines were also radioresistant relative to their respective parental lines, regarding cell proliferation and apoptosis. However, the two cetuximab resistant cell lines were not cross-resistant to erlotinib.
Conclusions
Acquired resistance to cetuximab was found to correlate with radiation-resistance but not erlotinib-resistance. Since cetuximab is an anti-EGFr monoclonal antibody and erlotinib is an anti-EGFr tyrosine kinase inhibitor, further studies are underway to investigate the role of downstream signaling events that may contribute to our understanding for the lack of cross-resistance between cetuximab and erlotinib.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
J. A. Bonner.
Funding
Has not received any funding.
Disclosure
J.A. Bonner: Financial Interests, Personal, Advisory Board: Merck Serono. All other authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract